The Placer Sentinel
Like Us On Facebook Follow Us On Twitter
 
Founded 1987
Serving Auburn and Placer County
 
  Home Community Finance Employment Your Home Your Money Your Kids Your Health  
  Business Education Politics Police & Fire Veterans' News Real Estate Consumer News Taxes  
  Church Food Recipes Gardening Car Care Fashion Beauty Pets  
  Lifestyles Sports Feature Writers Entertainment Environment Human Interest Technology Travel  
 
Gamefly
Placer Sentinal and Rainbow Rewards
In Association with Amazon.com



Your Health

FDA Approves JUVÉDERM® XC, The Latest Advancement In Hyaluronic Acid Dermal Fillers From Allergan, Inc., For A More Comfortable Injection Experience

Posted: 6/9/2010

FDA Approves JUVÉDERM XC

(NAPSA) - There’s encouraging news for anyone looking to instantly smooth the wrinkles around the nose and mouth but is concerned about pain. Now available nationwide, JUVÉDERM® XC from Allergan, Inc. contains li - docaine for enhanced comfort during treatment of the “parentheses” lines between the nose and mouth.

“The ‘no pain, no gain’ mentality has definitely played a role in the way women over the years have thought about aesthetic treatments. However, that is changing with recent advancements in aesthetic medicine,” said Amy Wechsler, M.D., board-certified dermatologist and psychiatrist. “In the clinical trial leading up to the U.S. Food and Drug Administration (FDA) approval of JUVÉDERM® XC, 93 percent of patients reported less pain when treated with JUVÉDERM® XC compared to the non-lidocaine JUVÉ- DERM® formulation1. Patients can now receive the same smooth results as demonstrated with JUVÉDERM® but enjoy a more comfortable injection experience.”

JUVÉDERM® XC with 0.3 percent lidocaine numbs the treatment area within seconds, po - tentially reducing the need for an additional anesthetic. Before the introduction of JUVÉDERM® XC, it often took up to 30 minutes for an anesthetic block to take effect. The new formulation provides the same smooth, longlasting results as demonstrated with existing formulations of JUVÉDERM® and now of fers a more comfortable treatment experience and potentially less time spent in the physician’s office compared to the non-lidocaine JUVÉDERM® formulation.

“JUVÉDERM® is the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment2,” said Dr. Wechsler. “My patients are satisfied with treatment results, and JUVÉDERM® has steadily gained popularity since its introduction.”

For more information about JUVÉDERM® dermal fillers and to find a local physician, please visit www.Juvederm.com and become a fan of the official JUVÉDERM® Facebook page.

Funnies Extra
Messenger Publishing Group

Advertise With Us
About the Sentinel
Get Home Delivery
Classified Ad Special
Letters to the Editor
Previous Issues

 
Front Page Sports
MBK Homes

Legal Advertising Hotline
Call Dan Direct at
916-532-2113
dan@carmichaeltimes.com
Legal Advertising Rates

 





Top Stories
 

California News
 



The Placer Sentinel | Copyright Notice
The Placer Sentinel | Paul V. Scholl, Publisher
Telephone: 530-823-2463 | Fax Line 916-773-2999
Email: publisher@PlacerSentinel.com | Site Designed and Hosted by TheSiteBarn.com

Like Us On Facebook Follow Us On Twitter